MREO News and Press, Mereo BioPharma Group From 12/19/21

Penny Stocks to Watch as 2021 Comes to an End As 2021 comes to an end, investors continue to search for the best penny stocks to buy . Although it can be challenging given the sheer number of penny stocks out there and factors at play, there are many ways to make money with ...

LONDON and REDWOOD CITY, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced the presentation of data from...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

MREO is a British company developing a new kind of monoclonal antibody for cancer. The company's self-owned pipeline is in the early stage. They recently announced interim data from a phase 1b trial. For further details see: Mereo BioPharma: Anti-TIGIT Developer In Mid-S...

Mereo BioPharma Group (NASDAQ:MREO) pops 7% premarket after announcing interim efficacy, safety, and biomarker data on patients from Phase 1b/2 ACTIVATE study of etigilimab, in combination with nivolumab in select recurrent advanced / metastatic solid tumors. The ACTIVATE study aims...

One complete response, one partial response and four cases of stable disease observed among 15 patients in the efficacy analysis set Etigilimab was well tolerated with a favorable safety profile Conference call today at 8:30am ET LONDON and REDWOOD CITY...

LONDON and REDWOOD CITY, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight,...

LONDON and REDWOOD CITY, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced that data from an investigato...

Context Therapeutics is developing a potentially best-in-class Progesterone Receptor Antagonist that has already been validated in several female cancer indications. Biotech IPOs have accelerated throughout the pandemic with 76 companies raising in 2020 and 81 IPOs through the end of ...

LONDON and REDWOOD CITY, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or the “Company”, a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced that the U.S. Food and Drug Ad...